Two weeks after reports emerged of a gene editing death in China of a 6-year-old girl treated for Snijders Blok-Campeau syndrome, Chinese company Huidagene Therapeutics Co. Ltd. disclosed the death of ...
A child died after receiving an experimental gene editing treatment in China, but the company developing the therapy did not publicly disclose the death until nearly a year later. Shanghai-based ...
The scientific world was rocked last month, when the case of a six-year-old girl who died in China, surfaced. The child was believed to have Snijders Blok-Campeau syndrome, a rare neurodevelopmental ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Three months before a young boy died in ...
The death of a 6-year-old girl allegedly linked to an experimental gene-editing clinical trial in Shanghai has sparked widespread concern over the safety and ethical oversight of medical research ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Last year, a little-known Chinese startup ...
Doctors have long debated how to balance the need for safety in gene therapy trials with the urgency of developing treatments for children with incurable, often worsening conditions. Reading time 11 ...
Dremone Francis, accused in the death of Harris County deputy Fernando Esqueda, will be held without bail after a surprise ...
Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. said its injectable neuroprotective agent, MT-200605, met phase II endpoints in acute ischemic stroke. MT-200605 ...
Joint owners or beneficiaries of the deceased person's account can work with the bank directly to access the funds. If the account becomes part of the owner's estate, the legally designated executor ...
Abelzeta Pharma Inc. regained all rights to prizloncabtagene autoleucel (C-CAR039), an anti-CD20/CD19 bispecific CAR T therapy, after Janssen Biotech Inc. discontinued development. As previously ...